Pulsing Ultrasound at Kidneys Can Lower Blood Pressure When Medications Donât
Source: Hush Naidoo/ Unsplash
May 18, 2021
In about a third of all patients prescribed medications to lower elevated blood pressure (BP) levels, the drugs do not work or patients fail to take them as directed.
“There are a variety of effective medications for lowering blood pressure, but many people need to take several drugs to control their hypertension, which can have side effects. In addition, many people simply don’t want to take additional medications and are poorly adherent to them,” says Ajay Kirtane, MD, professor of medicine at Columbia University Vagelos College of Physicians and Surgeons, and an interventional cardiologist at NewYork-Presbyterian/Columbia University Irving Medical Center.
Dapagliflozin Misses in COVID-19 but Intriguing Signal of Benefit medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
May 18, 2021
Patients with stable coronary artery disease who received “complete” revascularization in the ISCHEMIA trial appear to have derived more clinical benefit with the invasive strategy than medical therapy over follow-up, a finding at odds with what was observed for the overall trial. The implication, say investigators, is that revascularization might offer clinical advantages over conservative medical therapy if all anatomically relevant lesions are treated.
This analysis, which focused only on the patients who had complete revascularization defined anatomically, showed that the primary composite endpoint occurred in 11.9% of patients treated invasively as opposed to 15.4% of patients who were treated medically.
Dapagliflozin Did Not Significantly Reduce Organ Failure or Death in High-Risk Hospitalized COVID-19 Patients
Phase III DARE-19 trial shows SGLT2 inhibitor is well-tolerated in acutely ill patients
Dapagliflozin did not significantly reduce organ failure or death in high-risk hospitalized COVID-19 patients in the DARE-19 trial results, presented at ACC.21.
May 18, 2021 Dapagliflozin (Farxiga), a sodium-glucose co-transporter 2 (SGLT2) inhibitor, did not significantly reduce the risk of organ failure or death or improve recovery in patients hospitalized with COVID-19 (SARS-CoV-2) who are at high risk of developing serious complications compared to placebo, according to data presented at the American College of Cardiology (ACC) 2021 Scientific Session.
Share this article
Share this article
IRVINE, Calif., May 18, 2021 /PRNewswire/ Edwards Lifesciences (NYSE: EW) today announced the results of a real-world study comparing outcomes for patients with bicuspid aortic stenosis (AS) who were treated with SAPIEN 3 and SAPIEN 3 Ultra Transcatheter Aortic Valve Replacement (TAVR) and at low risk of death from surgery. The data show excellent outcomes at one year, with low rates of death and stroke, and no significant differences in the primary outcomes compared with the overall cohort, or those with tricuspid aortic valve disease.
The propensity-matched analysis comparing real-world data of bicuspid and tricuspid AS patients collected from the Society of Thoracic Surgeons and American College of Cardiology (STS/ACC) Transcatheter Valve Therapy (TVT) Registry was presented today during the EuroPCR 2021 late-breaking clinical trials hotline session by Raj Makkar, M.D., Director, Interventional Cardiology, Associate Director, Smidt Hear